BH3 mimetics potentiate pro-apoptotic activity of encorafenib in BRAFV600E melanoma cells.
Sign Up to like & getrecommendations! Published in 2020 at "Cancer letters"
DOI: 10.1016/j.canlet.2020.11.036
Abstract: BRAFV600- and MEK1/2-targeting therapies rarely produce durable response in melanoma patients. We investigated five BRAFV600E melanoma cell lines derived from drug-naïve tumor specimens to assess cell death response to encorafenib (Braftovi), a recently FDA-approved BRAFV600… read more here.
Keywords: brafv600e melanoma; apoptosis; bcl; cell ... See more keywords